AUPH Aurinia Pharmaceuticals Earnings and EPS analysis

Relative Growth: Rel. Growth: 89

Relative Strength: Rel. Strength: 42

Relative Valuation: Rel. Valuation: 91

Relative Profitability: Rel. Profitability: 99

EPS in 2026 (TTM): $2.36

Last Report Period Date: Jun 30, 2026

As of August 2026, according to Aurinia Pharmaceuticals's latest financial report, the company's current EPS (TTM) is $2.36. In 2025, the company recorded an earnings per share (EPS) of $2.14, which represents an increase compared to its EPS of $0.04 in 2024. Aurinia Pharmaceuticals's earnings per share for the quarterly report ending on Jun 30, 2026 was $0.29.

AUPH earnings history

Historical annual and quarterly earnings per share (EPS) data for Aurinia Pharmaceuticals

EPS (TTM)

$2.36

EPS Growth YoY (Quarterly)

81.3%

EPS (Quarterly)

$0.29

EPS Growth (Quarterly)

11.5%

The annual EPS in 2025 was $2.14, an increase of 5,250% from $0.04 in 2024. For the quarter ending Jun 30, 2026, the EPS was $0.29, showing a 81.3% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of June 2026 is $2.36. In 2024, the annual EPS was $0.04, showing an increase of 107.4% from 2023.

AUPH EPS vs price chart

AUPH EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

81.3%

EPS growth YoY

5,250%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

Aurinia Pharmaceuticals has recorded an increase in EPS of 81.3% over the last 12 months (YoY, quarterly).

AUPH Earnings Waterfall

Breakdown of revenue, profit and net income for Aurinia Pharmaceuticals

AUPH Earnings vs Peers

What are the earnings of AUPH compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
AUPH Aurinia Pharmaceuticals Inc	6.43	5,250%	N/A	N/A
QURE uniQure NV	N/A	29.7%	N/A	N/A
LXRX Lexicon Pharmaceuticals Inc	N/A	77.8%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.